Immutep Ltd (AU:IMM) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Immutep Limited has launched the TACTI-004 Phase III trial, a significant step towards establishing a new standard of care for metastatic non-small cell lung cancer. The trial will assess the efficacy of their LAG-3 immunotherapy, eftilagimod alfa, in combination with KEYTRUDA and chemotherapy. With approvals from Australia and anticipated global clearances, Immutep aims to enroll its first patient in early 2025, marking a pivotal moment for the company in the biotech sector.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
